Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada pharmaceutical company. Among 3 analysts tracked by Thomson/First Call, the average price target for ARNA is $4.5 but some of them are anticipating the price to move at the $6 level. Latest closing price was -60.59% below its 50-day moving average and -78.69% below its 200-day moving average.
Advertisement
In a statement, Concordia chairman and CEO Mark Thompson said that the Oakville, Ont. -based pharmaceutical company expects growth from its global segment “going forward will primarily come from new product launches”. 6909046 shares were traded on Concordia Healthcare Corp.’s last session.
In addition to this, the Canadian pharmaceutical company foresees fiscal year 2016 (FY16) revenue to fall in the $859-888 million range, as opposed to the Street’s estimate of $880.4 million.
A look at performance overview of Concordia Healthcare Corp. depicts that Performance (Week) is -26.03 percent while Performance Month is -42.25%. The Bid price in the last session was $5.13 x 700 and the Ask price was $5.45 x 200. Combining all the recommendations on Concordia Healthcare Corp (NASDAQ:CXRX), the mean now stands at 2.33.
Concordia Healthcare Corp. had a negative net margin of 81.80% and a positive return on equity of 25.18%. (NASDAQ:CXRX) last posted its quarterly earnings data on Friday, August 12th. The company earned $231.70 million during the quarter, compared to analyst estimates of $229.76 million. Taylor Asset Management Inc. boosted its position in Concordia Healthcare Corp.by 244.0% in the second quarter.
Recently stock market analysts updated their outstanding price targets on shares of Concordia Healthcare Corp.
In a statement issued on 9/19/2016 RBC Capital Markets fell the target price of Concordia Healthcare Corp (TSE:CXR) from $32 to $18 stating a possible upsideof 1.56%.
Institutional investors have recently made changes to their positions in the company. The company has a market cap of $275.49 million. HealthInvest Partners AB acquired a new position in Concordia Healthcare Corp. during the second quarter worth approximately $11,696,000. PCJ Investment Counsel Ltd. boosted its position in shares of Concordia Healthcare Corp.by 14.0% in the first quarter.
“[Concordia] will need to demonstrate growth from its global business, stability and North America, and substantial deleveraging before the stock can move higher”, Laurentian Bank Securities analyst Joseph Walewicz wrote in an August 15 note to clients, in which he also downgraded his rating on the stock to hold from buy. PCJ Investment Counsel Ltd. now owns 676,390 shares of the company’s stock worth $17,382,000 after buying an additional 83,000 shares in the last quarter.
Advertisement
10/16/2015 – Concordia Healthcare Corp. had its “buy” rating reiterated by analysts at S&P Capital IQ.
